Pluristem Therapeutics

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Retrieved on: 
Monday, July 25, 2022

As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol PLUR, CUSIP number 72942G 104.

Key Points: 
  • As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol PLUR, CUSIP number 72942G 104.
  • After nearly two decades as Pluristem, we are proud to expand as Pluri, leveraging our revolutionary technology to increase our market share across multiple verticals.
  • Pluris first collaboration, based on its innovative 3D cell-based technology platform, was formed in January 2022 to produce sustainable cultured food with Israeli food giant Tnuva Group.
  • Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the companys 3D cell-based technology to additional industries that require effective, mass cell production.

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Retrieved on: 
Wednesday, July 13, 2022

HAIFA, Israel, July 13, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (“Pluristem” or the “Company”), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study. The Company designed the study to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for hip fracture. The study enrolled 240 patients in the United States, Europe, and Israel.

Key Points: 
  • The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m.
  • ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA
    HAIFA, Israel, July 13, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (Pluristem or the Company), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study.
  • The Company designed the study to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for hip fracture.
  • This new data confirms the results demonstrated in Pluristems phase I/II study .

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Retrieved on: 
Monday, March 28, 2022

HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”), a leading biotechnology company, and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today announced that Pluristem’s CEO and President Yaky Yanay and Tnuva Group’s Chairman, Haim Gavrieli, will ring the Closing Bell at Nasdaq MarketSite in Times Square, New York. The ceremony, in honor of the companies’ launch of an innovative collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry, will take place on Monday, March 28, 2022 at 3:45 pm ET.

Key Points: 
  • We are honored to celebrate this important collaboration between Pluristem and Tnuva at Nasdaq, said Yaky Yanay, CEO and President of Pluristem.
  • Over the years, Pluristem has developed one of the most advanced cell-based technology platforms, offering mass-scale, cost-effective, consistent cell production.
  • Haim Gavrieli, Chairman of Tnuva Group: I am excited to note the groundbreaking collaboration between Pluristem and Tnuva Group.
  • Pluristem (Nasdaq: PSTI) is pushing the boundaries of science and engineering to produce cell-based products for various industries on a global scale.

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Retrieved on: 
Tuesday, March 8, 2022

Mr. Rosenthal also served as Executive Chairman of Fresh Start, a leading global food tech incubator backed by the Israel Innovation Authority, as well as top strategic and financial players.

Key Points: 
  • Mr. Rosenthal also served as Executive Chairman of Fresh Start, a leading global food tech incubator backed by the Israel Innovation Authority, as well as top strategic and financial players.
  • Food tech is on the rise and I am excited to be joining this new venture as we aim to transform the food system, especially the way we produce meat, said Mr. Rosenthal.
  • We believe that Eyal will position us as a leader in the global food tech industry, said Yaky Yanay, Chief Executive Officer and President of Pluristem.
  • Eyal is a food tech veteran and has an impressive track record as a trailblazer in the industry, said Eyal Malis, Chief Executive Officer of Tnuva Group.

Pluristem CEO Issues Shareholder Update

Retrieved on: 
Wednesday, March 2, 2022

HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.

Key Points: 
  • HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.
  • As I look ahead, I am more confident about the direction of Pluristem than ever before.
  • Pluristem is pushing the boundaries of science and engineering to create cell-based products for commercial use.
  • For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Retrieved on: 
Thursday, February 24, 2022

The collaboration is a major step forward to bringing sustainable cultured food to everyday consumers globally.

Key Points: 
  • The collaboration is a major step forward to bringing sustainable cultured food to everyday consumers globally.
  • Tnuva Group is the largest food producer in Israel, as well as the Israeli leader in the field of alternative dairy and protein products.
  • Tnuva holds Israels leading and most loved food brands in Israel, with approximately 4 million of Tnuva Groups products sold daily.
  • The collaboration with Tnuva supports Pluristems strategy to establish partnerships leveraging Pluristems cell-based technology platform.

Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Retrieved on: 
Monday, January 10, 2022

As part of the collaboration, the Parties may expand the collaboration to include cultured dairy and cultured fish products by establishing separate, new ventures.

Key Points: 
  • As part of the collaboration, the Parties may expand the collaboration to include cultured dairy and cultured fish products by establishing separate, new ventures.
  • Haim Gavrieli, Chairman of Tnuva Group: Our collaboration with Pluristem is part of the execution of Tnuva Groups strategy and vision.
  • We expect the collaboration between the companies to revolutionize the cultured food industry and develop the next generation of alternative proteins.
  • The collaboration with Tnuva supports Pluristem's strategy to establish partnerships that leverage its cell-based technology platform.

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Retrieved on: 
Monday, December 27, 2021

The primary efficacy endpoint was the number of ventilator free days (VFD) from day 1 through day 28 of the Studies.

Key Points: 
  • The primary efficacy endpoint was the number of ventilator free days (VFD) from day 1 through day 28 of the Studies.
  • VFD at day 60 and all-cause mortality at days 28 and 60 were part of the secondary efficacy endpoints in the Studies.
  • The Studies did not meet the primary efficacy endpoint of statistically significant improvement of VFD at 28 days.
  • These changes in the evolution of COVID-19 raised a major concern about the potential variability in the patient population in the Studies.

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

Retrieved on: 
Monday, July 19, 2021

Prof. Shalev has more than 30 years of experience working in clinical environments and research settings at the intersection of health and technology.

Key Points: 
  • Prof. Shalev has more than 30 years of experience working in clinical environments and research settings at the intersection of health and technology.
  • Prof. Shalev founded the Department of Medical Informatics at Maccabi Healthcare Services and was the head of Primary Care division of Maccabi Healthcare Services.
  • Mr. Birger served as the president and Chief Executive Officer of Elron from 2002 to 2009.
  • Pluristem is pushing the boundaries of science and engineering to reimagine pharmacological treatments and improve the standard of care.

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

Retrieved on: 
Thursday, July 8, 2021

The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel

Key Points: 
  • The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel
    HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the Company), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout.
  • Pluristem expects to announce the topline results of the readout during the fourth quarter of 2021.
  • PLX-PAD is currently in a Phase III multinational clinical trial testing the safety and efficacy of accelerating muscle regeneration following HIP fracture surgery.
  • For example, Pluristem is using forward-looking statements when it discusses the expected timing of the Phase II study clinical readout, the expected examination of the clinical readout in relating to treating ARDS for illnesses and causes in addition to COVID-19, the potential of its product candidates and its pipeline.